Stevanato Group demonstrated robust financial health in the second quarter of 2026, with overall revenue climbing to EUR 302 million, an 8% increase compared to the previous year. This growth was primarily propelled by the impressive performance of its Biopharmaceutical and Diagnostic Solutions (BDS) segment, which saw a 9% rise in revenue. The company's strategic pivot towards High-Value Solutions (HVS) proved successful, as HVS revenue surged by 16% and now constitutes 45% of total revenue. A significant achievement was the regulatory clearance for the Alina variable-dose pen platform across multiple European nations, marking a crucial step in the commercialization of its advanced drug delivery systems. Furthermore, Stevanato divested its Balda C. Brewer subsidiary, a move aimed at sharpening its focus on intricate biologic applications and integrated drug delivery technologies. The company’s financial projections for the entirety of 2026 remain positive, underpinned by sustained expansion in the biologics sector and its premium product offerings.
The company's financial and operational strategies in the first half of 2026 yielded results that were consistent with expectations. This performance underscores the enduring strength of its fundamental business operations and its adeptness at capitalizing on burgeoning opportunities within the biologics market, which is recognized as the most appealing and rapidly expanding sector. This positive momentum is a direct reflection of the robust demand for sophisticated containment and delivery solutions tailored for complex injectable therapies, including biosimilars, monoclonal antibodies, GLP-1 treatments, and other advanced medical interventions. With the increasing adoption of drug delivery devices by patients, pharmaceutical clients are increasingly seeking comprehensive partners who can integrate device innovation, manufacturing prowess, and supply chain dependability. Platforms such as Alina exemplify this strategy, showcasing Stevanato Group's capacity to merge drug containment and delivery device capabilities into a distinctive and commercially viable solution. The company believes it is uniquely positioned to address this evolving market landscape.
Strategic Shifts and Strong Financial Performance
In the second quarter of 2026, Stevanato Group reported a significant 8% year-over-year revenue increase, reaching EUR 302 million. This growth was largely fueled by a 9% rise in the Biopharmaceutical and Diagnostic Solutions (BDS) segment. A major factor contributing to this success was the company's commitment to High-Value Solutions (HVS), which experienced a 16% revenue growth and now represents 45% of the total revenue. This strategic focus is designed to enhance profitability and market position. The company also announced the successful divestiture of its Balda C. Brewer subsidiary, a move aimed at streamlining operations and allowing greater concentration on the highly specialized and integrated drug delivery systems essential for advanced biologic applications. This strategic realignment is part of Stevanato's broader plan to optimize its global footprint and accelerate its transition towards more complex and differentiated product offerings, thereby reinforcing its leadership in critical market segments.
The reported earnings highlighted several key financial metrics, including an adjusted EBITDA of EUR 78.7 million, a 21% increase from the previous year, with an adjusted EBITDA margin of 26%. Gross profit margin expanded by 60 basis points to 28.7%, driven by operational improvements at facilities in Latina and Fishers, and a more favorable mix of high-value solutions. Adjusted net profit rose 20% to EUR 37.6 million, and adjusted diluted EPS increased by 16.7% to EUR 0.14. GLP-1 related revenue accounted for 22% to 23% of total company revenue, demonstrating a visible contribution from this therapeutic area. Biologics revenue within the HVS segment saw a 30% increase, fueled by clinical evaluation and registration assets. The company's capital expenditures, totaling EUR 52 million, were strategically directed towards growth investments in new manufacturing plants and the Alina device program. Despite a negative free cash flow of EUR 32 million, reflecting significant investments in property, plant, and equipment, the company maintains robust liquidity to support its strategic objectives.
Innovation in Drug Delivery Systems and Market Expansion
A significant highlight for Stevanato Group in the second quarter of 2026 was the regulatory approval of its proprietary Alina variable-dose pen platform in several European countries. This achievement marks a pivotal commercial milestone, positioning Alina for diabetes and weight management applications. The company also launched Deora, a novel multi-use fixed-dose pen injector system, designed for treatments requiring precise patient adherence. These innovations underscore Stevanato’s commitment to addressing evolving customer needs by providing integrated solutions that combine device innovation, manufacturing expertise, and reliable supply chains. This strategic emphasis on advanced drug delivery systems, particularly those that enhance patient usability and adherence, strengthens the company’s competitive edge in the rapidly growing market for injectable biologics and GLP-1 therapies.
The company is strategically positioning itself to capitalize on the robust demand for injectable biologics, with over 9,000 assets currently in the global drug pipeline, more than 60% of which are biologics. This strong market trend, combined with increasing patient adoption of self-administered medicines, is reshaping pharmaceutical product development. Stevanato’s broad portfolio of drug delivery platforms and end-to-end capabilities are well-suited to support this evolution. The full ramp-up of the Fishers facility by the end of 2028 and the completion of the RTU 400 cartridge line in Latina by 2027 are key initiatives to expand capacity and meet future demand. Management emphasized that biologics now represent approximately 42% of revenue within the Biopharmaceutical and Diagnostic Solutions segment, a substantial increase from less than 20% in 2022. This demonstrates the company's successful pivot towards higher-value, differentiated solutions that cater to the complex requirements of modern pharmaceutical formulations and drug delivery.